NCT04143802View on ClinicalTrials.gov

A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 18, 2019

Primary Completion Date

December 28, 2020

Study Completion Date

December 28, 2020

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

LY3437943

Administered SC

DRUG

Dulaglutide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (4)

33143

Miami Research Associates, Miami

66219

PRA International, Lenexa

78229

Clinical Trials of Texas, Inc., San Antonio

92801

Anaheim Clinical Trials, LLC, Anaheim

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04143802 - A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) | Biotech Hunter | Biotech Hunter